Psoriatic arthritis

From 1055 new polyarthralgia presentations, 88 (8.3%) Dx w/ psoriatic arthritis. PsA Dx assoc w/ a +FamHx ( OR 4.14), psoriasis (OR=78.94), erosions (OR=5.74), US +power Doppler (OR=7.11). Neg assoc w/ +RF (OR 0.03), +CCP (OR 0.06). https://t.co/YXcqUq9JCi https://t.co/PLuU6cTDab

Links:

https://bit.ly/3Y7X1YF

Dr. John Cush @RheumNow( View Tweet )

Dec 08, 2022

Oligoarticular PsA: FOREMOST Study Dr. Peter Nash discusses abstract 1018 at ACR22 Convergence. Abstract 1018: Characterization of Joint Distribution and Disease Burden in Patients with Early Oligoarticular PsA: Results from the Ongoing FOREMOST Study https://t.co/3vkUQnpm9F https://t.co/h5OijjETUk

Links:

https://bit.ly/3h8ffbV

Dr. John Cush @RheumNow( View Tweet )

Dec 08, 2022

Xeljanz Cancer Risks Detailed
Save

MedPage Today

Dec 07, 2022

The degree to which the oral rheumatology drug tofacitinib (Xeljanz) seems to promote new malignancies is now fleshed out in the latest, and at least somewhat reassuring, report from a landmark safety study.

Tofacitinib at either 5 or 10 mg twice daily in the so-called ORAL

Read Article

Bimekizumab Efficacy in TNF-Refractory Psoriatic Arthritis
Save

Jack Cush, MD

Dec 07, 2022

Bimekizumab, a selective inhibitor of interleukin (IL)-17F and IL-17, has shown superior efficacy and safety in a 16 week trial in patients with active psoriatic arthritis who previously failed therapy with tumour necrosis factor-α (TNFi) inhibitors.

The BE COMPLETE study was a phase

Read Article

The Top 10 Research Priorities in Psoriatic Arthritis
Save

Jack Cush, MD

Dec 06, 2022

A survey of 317 carers and clinicians focused on psoriatic arthritis has set an agenda of the top 10 research questions for psoriatic arthritis (PsA).

A series of surveys were initated by the British Psoriatic Arthritis Consortium (BritPACT) and funded by the James Lind Alliance (JLA

Read Article

Comparing Biosimilar Growth in the US, Germany, and Switzerland
Save

Jack Cush, MD

Dec 05, 2022

The biosimilar landscape will change dramatically in 2023, following the successful rollouts in other countries in Europe. This analysis of the uptake and price of biologic therapy in Germany, Switzerland and the United States suggest that anticompetitive practices in the US could allow

Read Article

MTX side effects more prominent in PsA than RA pts. Study of 240 PsA & 86108 RA pts starting either MTX or TNFi. TNFi AE same betw PsA & RA, but MTX adverse greater in PsA (44.8% vs. 29.4%), especially N/V, abdominal pain, depression, tinnitus https://t.co/0QBc6sb900 https://t.co/FZibAeFDBx

Links:

https://bit.ly/3B6H2Af

Dr. John Cush @RheumNow( View Tweet )

Dec 05, 2022

Sleep Quality & PsA Abstract #0387 presented at #ACR22 attempted to shed light in this important quality of life determinant. 247 adult PsA patients were included in this study and their sleep quality was measured using the PSQI questionnaire. https://t.co/lLTnrh2yxG https://t.co/9ViEnEFE6c

Links:

https://bit.ly/3P2vKmd

Dr. John Cush @RheumNow( View Tweet )

Dec 05, 2022

Links:

https://bit.ly/3H6ZAnI

Dr. John Cush @RheumNow( View Tweet )

Dec 03, 2022

Differences in Presentation and Outcomes of Early vs Late Onset PsA Dr. Petryna ( @DrPetryna) discusses abstract 0377 presented at #ACR22. Abstract 0377: Differences in Early-onset vs. Late-onset PsA: Data from the RESPONDIA and REGISPONSER Studies https://t.co/3dwYmx7Hva https://t.co/ZFlFmWRbMK

Links:

https://bit.ly/3VqWUVU

Dr. John Cush @RheumNow( View Tweet )

Nov 26, 2022

Best of #ACR22 Day 2 in PSA -Efficacy and Safety Results from BE OPTIMAL in PsA -JAK inhibitors in rheumatic diseases -Who is the Winner? Switch vs Cycle in PsA -Women vs. Men: Response to Treatment in Seronegative Arthritis and more.https://t.co/JSKafxioMT https://t.co/Ov0VuCdX5y

Links:

https://bit.ly/3EGCQIr

Dr. John Cush @RheumNow( View Tweet )

Nov 26, 2022

Topic Podcasts - PsA Part1 Best of PsA on Day 1 #ACR22https://t.co/uXxUwy6u9G https://t.co/GDDXgcn2EC

Links:

https://bit.ly/3GGXhHQ

Dr. John Cush @RheumNow( View Tweet )

Nov 25, 2022

Are MDA criteria created equal in PsA? Dr. Rachel Tate ( @uptoTate ) reviews abstract #1496: Do Patients in MDA Report Low Disease Activity Regardless of Which of the MDA Criteria Are Met? Presented at #ACR22. https://t.co/H4wPHEV8D5 https://t.co/NqXYxXRNEX

Links:

https://bit.ly/3gs8mls

Dr. John Cush @RheumNow( View Tweet )

Nov 23, 2022

Pain in Psoriatic Arthritis
Save

Patricia Harkins, MD

Nov 22, 2022

The prioritisation of pain, and its evaluation, is important in those with psoriatic arthritis, when the already incredibly heterogenous nature of the condition can complicate assessment. Whilst we lean towards all pain in PsA being nociceptive in nature, evidence suggests that a significant

Read Article

Links:

https://bit.ly/3i31QBN

Dr. John Cush @RheumNow( View Tweet )

Nov 21, 2022

Patient Reported Outcomes in PsA Using Novel IL 17A Inhibitor Dr. Sims ( @DrCassySims) discusses abstract 0199 presented at #ACR22.https://t.co/L14WoimRE6 https://t.co/LhgyE1LwGa

Links:

https://bit.ly/3Xp5Z3w

Dr. John Cush @RheumNow( View Tweet )

Nov 21, 2022

Sleep Quality & Psoriatic Arthritis
Save

Olga Petryna, MD

Nov 15, 2022

For people living with psoriatic arthritis (PsA), the comfort of a good night's sleep may feel out of reach for many. Psoriatic arthritis is associated with a number of sleep problems, including trouble falling and staying asleep, poor-quality sleep and feeling sleepy during the day. Clinical

Read Article

ACR Best Abstracts - Day 3
Save

Jack Cush, MD

Nov 14, 2022

The last day was jammed with important reports and research including the late breaking abstracts.

Read Article

The complexity of opioid use in spondyloarthritis
Save

Robert Chao, MD

Nov 14, 2022

A few things we know about opioids: use is common; it’s not efficacious in the treatment of spondyloarthritis; and, there is an opioid epidemic and its users are stigmatized. Abstract 0402 is a retrospective study that looked at patients with psoriatic arthritis or ankylosing spondylitis in the

Read Article

Curtis et al. Primary non-adherence to csDMARDs and b/tsDMARDs in RA/PsA/SpA. Medicare and commerically-insured patients. 20-44%! of new prescriptions not filled by 6 months. Higher for csDMARDs than b/tsDMARDs @RheumNow #ACR22 Abstr#2199 https://t.co/Pwg6GKu7Gg https://t.co/wPF0pu1UDa

Links:

Primary Non-adherence to Biologics and Immunomodulatory Therapies for Rheumatoi…

Richard Conway @RichardPAConway( View Tweet )

Nov 14, 2022

Pain in #psoriaticarthritis might not be all inflammatory.. In this study presented by Dr F Sunzini: 👉PsA pts w/⬆️FM scores had⬆️functional brain connectivity bet mid-post IC & thalamus, phgyrus & PFC ..so consider nociplastic pain too & adjust mgt #ACR22 @RheumNow ABST#2256 https://t.co/suCAvx0pD5

sheila @RHEUMarampa( View Tweet )

Nov 14, 2022

BE OPTIMAL Study - Bimekizumab (IL-17A and IL-17F inhibitor) for treatment of PsA. Similar ACR 50 (~50%) response rates of Bimekizumab, adalimumab, and placebo (switched to BKZ at wk 16). ~60% PASI100 in BKZ #ACRBest Abs#L02 @RheumNow #ACR22 https://t.co/W2B2kyju9F

Robert B Chao, MD @doctorRBC( View Tweet )

Nov 14, 2022

Ritchlin et al. Bimekizumab in bDMARD naive PsA. 52 week results. Not surprisingly, week 16 outcomes sustained. No joint difference to ADA, skin slightly better @RheumNow #ACR22 Abstr#L02 https://t.co/RjCV8Hb3HR https://t.co/a0NQFyFZlt

Links:

Bimekizumab Treatment in Biologic DMARD-Naïve Patients with Active Psoriatic Ar…

Richard Conway @RichardPAConway( View Tweet )

Nov 14, 2022

A new murine model to study Pso and PsA! Immunodeficient mice NSG-SGM3 🐁 injected w/ serum & PBMCs from Pso and/or PsA pts = pro & arthritis (same phenotype than pts) Mice skin & synovia >effector memory CD8 T cell & < naïvehttps://t.co/cxSvEZC9LyAbs#L04 #ACR22 @Rheumnow https://t.co/hfbtSsP3f8

Links:

Psoriatic Arthritis Disease Subtypes Mediated by CD8 T Cells Are Phenocopied in…

Aurelie Najm @AurelieRheumo( View Tweet )

Nov 14, 2022

#L02 #acr22 @rheumnow Bimekizumab ph3 in PsA: meaningful clinical improvement, improved mTSS, no new safety signals. Wk 52 ACR50: 53.0% PBO/BKZ, 54.5% BKZ, 50.0% ADA; MDA 53.7% PBO/BKZ, 55.0% BKZ, 52.9% ADA . mTSS change from baseline ≤0.5): 87.3% PBO/BKZ, 89.3% BKZ, 94.1% ADA https://t.co/NYRrPUBjt1

Olga Petryna @DrPetryna( View Tweet )

Nov 14, 2022

Recent Blogs

From the Archives: Rheumatology Dead Word Cemetery
Save

Jack Cush, MD

Oct 31, 2022

I recently heard of a secondary school assignment wherein students were challenged to “bury” a word that was no longer useful or appropriate. Their exercise has now evolved into an unofficial RheumNow task force to retire diagnostic terms that have grown into misuse in rheumatology and medicine. How did we decide which words should perish? And by what criteria? Who has the final say? Read Post